Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 10, 2014, Pages 1423-1432

  Müller, Thomas ^a  

^a St Joseph Hospital Berlin Weissensee   (Germany)

Author keywords

Dopamine substitution; Glutamate; Monoaminooxidase B inhibition; NMDA antagonism; Parkinson's disease; Rasagiline; Selegiline

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; RASAGILINE; SELEGILINE; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; INDAN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; NITRILE;

ARTICLE; CHEMICAL STRUCTURE; DOPAMINERGIC TRANSMISSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; NERVE CELL NECROSIS; NEUROPROTECTION; PARKINSON DISEASE; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); TURNOVER TIME; ANIMAL; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECTS; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; CATECHOLS; DISEASE PROGRESSION; HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; NITRILES; OXIDATIVE STRESS; PARKINSON DISEASE; SELEGILINE;

EID: 84907180256     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.943182     Document Type: Article

References (90)

1. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S21-3
2. Rajput AH, Birdi S. Epidemiology of Parkinson's disease. Parkinsonism Relat Disord 1997;3(4):175-86
3. Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: Conceptual aspects. J Neural Transm 2004;111(2):201-16
4. Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009;72(Suppl 7):S32-8
5. Clarke CE, Patel S, Ives N, et al. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord 2011;26(7):1187-93
6. Müller T, Pietsch A. Comparison of gait training versus cranial osteopathy in patients with Parkinson's disease: A pilot study. NeuroRehabilitation 2013;32(1):135-40
7. Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease [abstract]. Cochrane Database Syst Rev 2013;9:CD002817
8. van Nimwegen M, Speelman AD, Overeem S, et al. Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: Randomised controlled trial. BMJ 2013;346:576-81
9. Foster ER, Golden L, Duncan RP, Earhart GM. Community-based Argentine tango dance program is associated with increased activity participation among individuals with Parkinson's disease. Arch Phys Med Rehabil 2013;94(2):240-9
10. Gao Q, Leung A, Yang Y, et al. Effects of Tai Chi on balance and fall prevention in Parkinson's disease: A randomized controlled trial. Clin Rehabil 2014. [Epub ahead of print
11. Müller T, Muhlack S. Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2010;81(7):747-53
12. Müller T. Drug therapy in patients with Parkinson's disease. Transl Neurodegener 2012;1(1):10
13. Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine( = DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr 2001;113(22):851-4
14. Hubsher G, Haider M, Okun MS. Amantadine: The journey from fighting flu to treating Parkinson disease. Neurology 2012;78(14):1096-9
15. Eggert K, Larisch A, Dodel R, et al. Awareness and knowledge of the clinical practice guideline on Parkinson's disease among German neurologists. Eur Neurol 2009;61(4):216-22
16. Ehret R, Balzer-Geldsetzer M, Reese JP, et al. [Direct costs for Parkinson's treatment in private neurology practices in Berlin]. Nervenarzt 2009;80(4):452-8
17. Larisch A, Reuss A, Oertel WH, Eggert K. Does the clinical practice guideline on Parkinson's disease change health outcomes? A cluster randomized controlled trial. J Neurol 2011;258(5):826-34
18. Moller JC, Korner Y, Dodel RC, et al. Pharmacotherapy of Parkinson's disease in Germany. J Neurol 2005;252(8):926-35
19. Schroder S, Kuessner D, Arnold G, et al. Do neurologists in Germany adhere to the national Parkinson's disease guideline? Neuropsychiatr Dis Treat 2011;7:103-10
20. Kovacs N, Janszky J, Nagy F. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation. Drugs Aging 2011;28(2):161-2
21. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368(7):610-22
22. Kirsch-Darrow L, Mikos A, Bowers D. Does deep brain stimulation induce apathy in Parkinson's disease? Front Biosci 2008;13:5316-22
23. Smeding HM, Speelman JD, Huizenga HM, et al. Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease. J Neurol Neurosurg Psychiatry 2011;82(7):754-60
24. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: A randomised, multicentre study. Lancet Neurol 2008;7(7):605-14
25. Romito LM, Albanese A. Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: A review of 5-year reports. J Neurol 2010;257(Suppl 2):S298-304
26. Zibetti M, Cinquepalmi A, Angrisano S, et al. Management of antiparkinsonian therapy during chronic subthalamic stimulation in Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 4):S76-80
27. Hassan A, Wu SS, Schmidt P, et al. What are the issues facing Parkinson's disease patients at ten years of disease and beyond? Data from the NPF-QII study. Parkinsonism Relat Disord 2012;18(Suppl 3):S10-14
28. Oyama G, Okun MS, Schmidt P, et al. Deep brain stimulation may improve quality of life in people with Parkinson's disease without affecting caregiver burden. Neuromodulation 2014;17(2):126-32
29. Soileau MJ, Persad C, Taylor J, et al. Caregiver burden in patients with Parkinson disease undergoing deep brain stimulation: An exploratory analysis. J Parkinsons Dis 2014. [Epub ahead of print
30. Hauser R, Stocchi F, Rascol O, et al. Phase-3 clinical trials of adjunctive therapy with preladenant, an adenosine 2a antagonist, in patients with Parkinson's disease [abstract]. Neurology 2014;82(Suppl 10):P7.087
31. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. Mov Disord 2007;22(2):179-86
32. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008;23(5):700-7
33. Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopainduced dyskinesias. Parkinsonism Relat Disord 2014. [Epub ahead of print
34. Pilleri M, Antonini A. Novel levodopa formulations in the treatment of Parkinson's disease. Expert Rev Neurother 2014;14(2):143-9
35. Muhlack S, Herrmann L, Salmen S, Müller T. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. J Neural Transm 2014. [Epub ahead of print
36. Ngwuluka N, Pillay V, Du Toit LC, et al. Levodopa delivery systems: Advancements in delivery of the gold standard. Expert Opin Drug Deliv 2010;7(2):203-24
37. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: A multicentre study. J Neurol Neurosurg Psychiatry 2014. [Epub ahead of print
38. Perez-Lloret S, Rey MV, Crispo J, et al. Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. Expert Opin Drug Saf 2014;13(3):351-60
39. Müller T, Hoffmann JA, Dimpfel W, Oehlwein C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease. J Neural Transm 2013;120(5):761-5
40. Dimpfel W, Hoffmann JA. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 2011;11:2-7
41. Müller T. Current status of safinamide for the drug portfolio of Parkinson's disease therapy. Expert Rev Neurother 2013;13(9):969-77
42. Bartl J, Müller T, Grunblatt E, et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 2014;121(4):379-83
43. Riederer P, Laux G. MAO-inhibitors in Parkinson's Disease. Exp Neurobiol 2011;20(1):1-17
44. Teo KC, Ho SL. Monoamine oxidase-B( MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease. Transl Neurodegener 2013;2(1):19-27
45. Rascol O. Rasagiline in the pharmacotherapy of Parkinson's disease-a review. Expert Opin Pharmacother 2005;6(12):2061-75
46. Hoy SM, Keating GM. Rasagiline: A review of its use in the treatment of idiopathic Parkinson's disease. Drugs 2012;72(5):643-69
47. Fahn S, McCall WV, Hammon J, et al. The effect of high dose orally disintegrated tablet selegiline, a selective monoaminoxidase B inhibitor, on monoaminoxidase A, and compared to EMSAM (transdermal formulation of selegiline). Neurology 2011;1(Suppl 4):275
48. Bar-Am O, Yogev-Falach M, Amit T, et al. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004;89(5):1119-25
49. Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 2005;19(13):1899-901
50. Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem 2007;103(2):500-8
51. Bar-Am O, Weinreb O, Amit T, Youdim MB. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem 2010;112(5):1131-7
52. Naoi M, Maruyama W, Inaba-Hasegawa K. Revelation in the neuroprotective functions of rasagiline and selegiline: The induction of distinct genes by different mechanisms. Expert Rev Neurother 2013;13(6):671-84
53. Naoi M, Maruyama W, Yi H. Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SHSY5Y cells through suppression of cytochrome c release from mitochondria. J Neural Transm 2013;120(11):1539-51
54. Jenner P, Langston JW. Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline. Mov Disord 2011;26(13):2316-23
55. Lewitt PA. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. Clin Neuropharmacol 2007;30(5):305-7
56. Brotchie J, Johnston TH, Visanji NP. 1-Aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl 2):102
57. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005;45(8):878-94
58. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007;29(9):1825-49
59. Burke WJ. MAO-B inhibitor know-how: Back to the pharm. Neurology 2009;73(23):2048
60. Müller T. Detoxification and antioxidative therapy for levodopainduced neurodegeneration in Parkinson's disease. Expert Rev Neurother 2013;13(6):707-18
61. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-78
62. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol 2002;59(12):1937-43
63. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-6
64. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000;23(6):324-30
65. Elmer LW. Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 2013;19(11):930-6
66. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol 2005;62(2):241-8
67. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
68. Barone P, Fernandez HH, Ferreira J, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: Results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic parkinson disease( PD) patients (MOTION Study). Neurology 2013;80:Meeting Abstracts 1
69. Hauser RA, Silver D, Choudry A, Isaacson S. A placebo controlled, randomized, double-blind study to assess the safety and clinical benefit of rasagiline as an add-on therapy to dopamine agonist monotherapy in early Parkinson's disease (PD): The ANDANTE study. Neurology 2013;80:Meeting Abstracts 1
70. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-78
71. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction? Neurology 2010;74(14):1143-8
72. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): Prespecified and posthoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
73. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): Prespecified and posthoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
74. Lew MF. Rasagiline treatment effects on parkinsonian tremor. Int J Neurosci 2013;123(12):859-65
75. Stocchi F. The concept of continuous dopaminergic stimulation: What we should consider when starting Parkinson's disease treatment. Neurodegener Dis 2010;7(1-3):213-15
76. de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V. Trials of neuroprotective therapies for Parkinson's disease: Problems and limitations. Parkinsonism Relat Disord 2010;16(6):365-9
77. Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the nonhuman primate: Comparison of rasagiline( TVP 1012) with selegiline. J Neural Transm 2001;108(8-9):985-1009
78. Kronstrand R, Andersson MC, Ahlner J, Larson G. Incorporation of selegiline metabolites into hair after oral selegiline intake. J Anal Toxicol 2001;25(7):594-601
79. Kronstrand R, Ahlner J, Dizdar N, Larson G. Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. J Anal Toxicol 2003;27(3):135-41
80. Laine K, Anttila M, Huupponen R, et al. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 2000;23(1):22-7
81. Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Rasagiline - A novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag 2007;3(3):467-74
82. Thorpy M. Therapeutic advances in narcolepsy. Sleep Med 2007;8(4):427-40
83. Hublin C, Partinen M, Heinonen EH, et al. Selegiline in the treatment of narcolepsy. Neurology 1994;44(11):2095-101
84. Roselaar SE, Langdon N, Lock CB, et al. Selegiline in narcolepsy. Sleep 1987;10(5):491-5
85. Thorpy MJ, Adler CH. Parkinson's disease and sleep. Neurol Clin 2005;23(4):1187-208
86. Taylor DJ. Insomnia and depression. Sleep 2008;31(4):447-8
87. Rodnitzky RL, Narayanan NS. Amantadine's role in the treatment of levodopa-induced dyskinesia. Neurology 2014;82(4):288-9
88. Lyytinen J, Kaakkola S, Ahtila S, et al. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Mov Disord 1997;12(4):497-505
89. Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidencebased medicine review update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2-41
90. Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004;19(8):916-23